Application | Comment | Organism |
---|---|---|
medicine | design of inhibitors may lead to effective neuroprotective agents, possibility to employ GCPII inhibitors in stroke therapy | Rattus norvegicus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(t-Bu)Cys-PSI[C-O]-Glu | IC50: 29 nM | Rattus norvegicus | |
2-(phosphonomethyl)pentanedioic acid | IC50: 5.1 nM | Rattus norvegicus | |
Asp-Glu | - |
Rattus norvegicus | |
Asp-PSI[C-O-S]-Glu | IC50: 0.0461 mM | Rattus norvegicus | |
Asp-PSI[C-O]-Asp | IC50: 0.0038 mM | Rattus norvegicus | |
Asp-PSI[S]-Asp | 0.1 mM, 42% inhibition | Rattus norvegicus | |
Cys-PSI[C-O-S]-Glu | IC50: 6.9 nM | Rattus norvegicus | |
D-Glu-PSI[C-O]-D-Glu | 0.1 mM, 67% inhibition | Rattus norvegicus | |
D-Glu-PSI[C-O]-Glu | 0.001 mM, 25% inhibition | Rattus norvegicus | |
Glu-Glu | - |
Rattus norvegicus | |
Glu-PSI[C-O-C-O]-Glu | 0.001 mM, 9% inhibition | Rattus norvegicus | |
Glu-PSI[C-O]-Glu | IC50: 47 nM | Rattus norvegicus | |
Gly-PSI[C-O-S]-Glu | 0.001 mM, 46% inhibition | Rattus norvegicus | |
t-BuNHC(O)-Glu | 0.001 mM, 10% inhibition | Rattus norvegicus | |
[HO2C(CH2)2CH(CO2H)CH2]2P(O)(OH) | - |
Rattus norvegicus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Rattus norvegicus | - |
- |
- |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.0000051 | - |
IC50: 5.1 nM | Rattus norvegicus | 2-(phosphonomethyl)pentanedioic acid | |
0.0000069 | - |
IC50: 6.9 nM | Rattus norvegicus | Cys-PSI[C-O-S]-Glu | |
0.000029 | - |
IC50: 29 nM | Rattus norvegicus | (t-Bu)Cys-PSI[C-O]-Glu | |
0.000047 | - |
IC50: 47 nM | Rattus norvegicus | Glu-PSI[C-O]-Glu | |
0.0038 | - |
IC50: 0.0038 mM | Rattus norvegicus | Asp-PSI[C-O]-Asp | |
0.0461 | - |
IC50: 0.0461 mM | Rattus norvegicus | Asp-PSI[C-O-S]-Glu |